- In June 2024, doctors began utilizing the new Duo stent developed by Koninklijke Philips N.V., following its approval by the FDA. This stent is designed to assist patients with chronic vein issues (CVI) that result in blood flow blockages. The Duo stent offers an advanced solution for improving circulation in patients suffering from these conditions
- In January 2024, VVT Med Ltd. (VVT Medical) entered into a strategic distribution partnership with Methapharm Inc. to distribute its ScleroSafe platform for treating varicose veins in the U.S. This collaboration aims to expand the reach of the innovative ScleroSafe technology, enhancing treatment options for varicose vein patients. The partnership marks a significant step in bringing advanced varicose vein treatment solutions to the U.S. market
- In June 2023, Theraclion received approval from the U.S. FDA to launch a pivotal clinical study assessing the effectiveness of Sonovein for treating primary insufficiency of the great saphenous veins. This study aims to further evaluate the potential of Sonovein as a non-invasive treatment for venous insufficiency. The FDA approval marks a significant step forward in advancing the clinical application of Sonovein in the U.S. market
- In April 2022, I-VASC, an Italy-based medical device company, secured EUR 1.8 million in Series A funding to advance its VELEX device. The VELEX device is designed for the treatment of varicose veins, offering an innovative solution in the field. This investment aims to support the development and market expansion of the device, enhancing treatment options for varicose vein patients
